Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Pulmonology
•
EGPA
•
Eosinophilic granulomatosis with polyangiitis
•
Asthma
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
Do you consider benralizumab for patients with EGPA with severe pulmonary symptoms on mepolizumab?
Related Questions
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How would you approach failure of maintenance therapy (Azathioprine) for PR3 positive, c-ANCA positive, pulmonary–renal vasculitis previously induced with cyclophosphamide, with a history of anaphylaxis to rituximab?
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
How frequently do you monitor CT scans, PFTs, and TTEs in patients with ILA or mild ILD?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
How do you approach management of osteoporosis in patients post lung transplant?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?